Thursday, December 20, 2018, 12:00 AM - Monday, December 20, 2021, 12:00 AM PST

Internet Enduring Material Sponsored by the Stanford University School of Medicine. Presented by the Department of Medicine, division of Endocrinology, Gerontology and Metabolism at the Stanford University School of Medicine.

This CME activity provides a practical approach to lifestyle and medication management for type 2 diabetes mellitus. The course will take the learner through a case-based learning activity focusing on new medications and medication algorithms. Note: Insulin therapy is not addressed in this course. The course will also address culturally sensitive food-based counseling to facilitate lifestyle modifications.

Intended Audience
This course is designed for physicians and allied health professionals in cardiology, family practice, primary care, internal medicine, neurology and oncology.

Release Date: December 20, 2018

Expiration Date: December 20, 2021

Estimated Time to Complete:  1.25 Hours

CME Credits Offered: 1.25

Registration Fee: FREE

AMA PRA Category 1 Credits™ (1.25 hours), Non-Physician Participation Credit (1.25 hours)

1. Recognize the new/most recent treatment options for type 2 diabetes.
2. Evaluate patients for appropriate treatments and comorbidities.
3. Evaluate patients for medication/ treatment adherence.
4. Formulate progression of treatment plans for patients who haven't improved on current regimens.
5. Use culturally sensitive communication tactics when discussing importance and safety of medication and treatment adherence with patients.

The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Stanford University School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™from organizations accredited by the ACCME. Please check with your state’s credentialing board for their requirements.

Accessibility Statement
 
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, please contact the CME Conference Coordinator.

Cultural and Linguistic Competency

The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html

Bibliography

Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular out-comes in type 2 diabetes. N Engl J Med 2016;375:311-322

Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 random-ized trial. Circulation. 2014;130:1579–1588. doi: 10.1161/CIRCULATIONAHA.114.010389.

EXAMINE trial: 
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076. doi: 10.1016/S0140-6736(14)62225-X.

Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009 Mar;25(3):569–83. 2009. [PubMed] 2015.

For a complete list, please view the References/Bibliography page in the Course.

The registration form for this activity is currently unavailable.

Disclosures:
The following planners, authors and speakers have indicated that that they have no relationships with industry to disclose relative to the content of this activity:

Marina Basina, MD
Clinical Associate Professor of Medicine - Endocrinology, Gerontology and Metabolism
Stanford University School of Medicine
Course Director
Speaker

Leticia Wilke, CNS
Clinical Nurse Specialist
Stanford Health Care
Author

Leah Groppo, MS, RD, CDE
Clinical Dietitian
Stanford Health Care
Author

Kathleen Judge, CNS
Clinical Nurse Specialist
Stanford Health Care
Author, Speaker

Stanford University School of Medicine has received and has used undesignated program funding from Pfizer, Inc. to facilitate the development of innovative CME activities designed to enhance physician competence and performance and to implement advanced technology. 

A portion of this funding supports this activity.